- recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors
This study is testing a new drug, BLU-222, for people with certain advanced cancers, including breast, ovarian, and stomach cancers. It aims to see how safe the drug is, how it moves through the body, and if it helps shrink tumors, both on its own and with other treatments.
France · Italy · Belgium - recruitingPHASE4
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
This study looks at how well a breast cancer drug called ribociclib works for women with a specific type of advanced breast cancer and why it might or might not work. It also checks for side effects and how patients feel.
Germany - recruitingPHASE3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
This study compares two drug combinations, RLY-2608 with fulvestrant, and capivasertib with fulvestrant, for advanced breast cancer that has a specific gene change (PIK3CA mutation) and has grown after previous treatment. It's for HR+/HER2- breast cancer.
United States · Argentina · Australia - recruitingPHASE3
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
This study is testing a new drug, capivasertib, for advanced breast cancer that's grown despite previous treatment. It aims to see how well it works and if it improves quality of life for patients.
Belgium · Germany · Portugal - recruitingPHASE1, PHASE2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
This study is testing a new drug, rezatapopt, for advanced cancers with a specific gene change (TP53 Y220C). It's also looking at rezatapopt with another drug, pembrolizumab, to see how safe and effective they are. It’s for people who have already had cancer treatment.
United States · Australia · France - recruitingPHASE2
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
This study looks for tiny traces of cancer DNA in the blood to find early signs of breast cancer coming back. If found, it tests if a new treatment combination (Palbociclib and Fulvestrant) works better than standard treatment for ER-positive, HER2-negative breast cancer.
France · United Kingdom - recruitingPHASE3
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
This study is for people with advanced ER+/HER2- breast cancer with an ESR1 gene change, whose cancer has grown despite previous treatments. It tests a new drug called elacestrant alongside an existing one, everolimus, to see if this combination works better at stopping the cancer from growing.
Austria · Brazil · Czechia